STEMPOINT CAPITAL LP
Reported holdings as of Q2 2026, from 11 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| TANGO THERAPEUTICS INC OPT | TNGX | $38.4M | 1,223,019 | +5.81pp | 2q | +204.4%+$25.8M | |
| ABIVAX SA | ABVX | $37.8M | 283,657 | -0.23pp | 5q | -54.8%-$45.8M | |
| REVOLUTION MEDICINES INC OPT | RVMD | $30.1M | 159,943 | -0.20pp | 4q | -71.6%-$75.9M | |
| ERASCA INC OPT | ERAS | $28.8M | 1,565,913 | +4.21pp | 2q | +226.4%+$20.0M | |
| TYRA BIOSCIENCES INC | TYRA | $20.2M | 632,754 | +2.00pp | 2q | +63.8%+$7.9M | |
| DIANTHUS THERAPEUTICS INC | DNTH | $19.6M | 200,851 | +1.99pp | 4q | +17.5%+$2.9M | |
| ENLIVEN THERAPEUTICS INC | ELVN | $17.6M | 346,914 | +0.28pp | 2q | -52.3%-$19.3M | |
| BIOHAVEN LTD OPT | BHVN | $16.4M | 1,064,200 | +0.22pp | 2q | -66.6%-$32.7M | |
| MINERALYS THERAPEUTICS INC | MLYS | $16.3M | 602,686 | +0.01pp | 7q | -43.5%-$12.5M | |
| SURROZEN INC | SRZN | $13.8M | 602,798 | +0.53pp | 9q | -16.5%-$2.7M | |
| KINIKSA PHARMACEUTICALS INTL | KNSA | $13.4M | 209,234 | - | new | NEW | |
| SCHOLAR ROCK HLDG CORP | SRRK | $13.2M | 239,146 | -7.67pp | 7q | -88.5%-$100.8M | |
| ALKERMES PLC | ALKS | $13.0M | 248,015 | +1.69pp | 2q | +54.1%+$4.6M | |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | $12.5M | 622,723 | - | new | NEW | |
| PRAXIS PRECISION MEDICINES I | PRAX | $12.5M | 37,243 | -1.35pp | 3q | -66.9%-$25.2M | |
| ROIVANT SCIENCES LTD OPT | ROIV | $12.4M | 348,408 | +0.07pp | 11q | -54.8%-$15.0M | |
| BIOAGE LABS INC | BIOA | $11.4M | 464,171 | +0.82pp | 2q | -31.5%-$5.2M | |
| CG ONCOLOGY INC | CGON | $11.3M | 159,349 | -0.73pp | 2q | -61.3%-$17.9M | |
| ORUKA THERAPEUTICS INC | ORKA | $11.1M | 116,461 | - | new | NEW | |
| IMMUNOVANT INC | IMVT | $10.7M | 276,527 | -1.79pp | 11q | -81.5%-$46.9M | |
| CELCUITY INC | CELC | $10.3M | 98,203 | +0.45pp | 4q | -18.2%-$2.3M | |
| RELMADA THERAPEUTICS INC | RLMD | $10.1M | 1,460,093 | +0.94pp | 2q | +22.2%+$1.8M | |
| CLIMB BIO INC | CLYM | $9.7M | 742,745 | - | new | NEW | |
| SPYRE THERAPEUTICS INC | SYRE | $9.5M | 106,926 | flat | 3q | -68.1%-$20.3M | |
| ZURA BIO LTD | ZURA | $8.1M | 1,368,215 | +0.53pp | 2q | -9.2%-$819.1K | |
| INFLARX NV | IFRX | $7.2M | 3,228,255 | - | new | NEW | |
| AMYLYX PHARMACEUTICALS INC | AMLX | $6.9M | 384,304 | -0.61pp | 4q | -71.3%-$17.2M | |
| CELLDEX THERAPEUTICS INC NEW | CLDX | $6.6M | 178,412 | -0.41pp | 2q | -64.9%-$12.3M | |
| OVID THERAPEUTICS INC | OVID | $6.5M | 2,417,283 | - | new | NEW | |
| EQUILLIUM INC | EQ | $6.5M | 2,016,607 | - | new | NEW | |
| DEFINIUM THERAPEUTICS INC | DFTX | $6.5M | 137,124 | -0.08pp | 2q | -78.9%-$24.2M | |
| CYTOKINETICS INC | CYTK | $6.4M | 75,603 | -0.54pp | 3q | -70.8%-$15.6M | |
| DAMORA THERAPEUTICS INC | DMRA | $5.6M | 216,194 | - | new | NEW | |
| INVENTIVA SA | IVA | $5.4M | 1,426,320 | - | new | NEW | |
| CENTURY THERAPEUTICS INC | IPSC | $5.3M | 2,146,182 | - | new | NEW | |
| AURA BIOSCIENCES INC | AURA | $5.1M | 714,280 | - | new | NEW | |
| EYEPOINT INC | EYPT | $4.8M | 338,471 | -1.18pp | 3q | -79.1%-$18.3M | |
| ASSEMBLY BIOSCIENCES INC | ASMB | $4.7M | 170,378 | -0.19pp | 4q | -54.1%-$5.5M | |
| WHITEHAWK THERAPEUTICS INC | WHWK | $4.7M | 1,021,037 | +0.18pp | 4q | -45.7%-$3.9M | |
| XENON PHARMACEUTICALS INC | XENE | $4.6M | 76,075 | -0.79pp | 4q | -73.0%-$12.4M | |
| PERSONALIS INC OPT | PSNL | $4.1M | 247,783 | - | new | NEW | |
| UNIQURE NV | QURE | $4.1M | 88,115 | +0.45pp | 7q | -43.6%-$3.1M | |
| COMPASS PATHWAYS PLC | CMPS | $4.0M | 284,769 | - | new | NEW | |
| AVALYN PHARMACEUTICALS INC | AVLN | $3.9M | 118,000 | - | new | NEW | |
| MAPLIGHT THERAPEUTICS INC | MPLT | $3.8M | 106,906 | +0.27pp | 3q | -46.5%-$3.3M | |
| ALUMIS INC | ALMS | $3.8M | 135,736 | -0.32pp | 2q | -70.4%-$9.1M | |
| AXSOME THERAPEUTICS INC | AXSM | $3.8M | 15,375 | - | new | NEW | |
| MONTE ROSA THERAPEUTICS INC | GLUE | $3.7M | 153,544 | - | new | NEW | |
| ACADIA PHARMACEUTICALS INC | ACAD | $3.6M | 143,167 | -0.42pp | 2q | -70.5%-$8.7M | |
| SOLID BIOSCIENCES INC | SLDB | $3.6M | 358,780 | +0.35pp | 2q | -8.2%-$319.9K | |
| CRESCENT BIOPHARMA INC. | CBIO | $3.3M | 182,382 | - | new | NEW | |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | $3.2M | 39,198 | - | new | NEW | |
| KODIAK SCIENCES INC | KOD | $3.0M | 75,872 | - | new | NEW | |
| PHARVARIS N V | PHVS | $2.8M | 80,907 | +0.01pp | 3q | -53.3%-$3.2M | |
| MONOPAR THERAPEUTICS INC | MNPR | $2.8M | 30,125 | - | new | NEW | |
| RAPPORT THERAPEUTICS INC | RAPP | $2.8M | 66,582 | - | new | NEW | |
| NEWAMSTERDAM PHARMA COMPANY | NAMS | $2.6M | 77,589 | -0.66pp | 6q | -78.5%-$9.6M | |
| SIONNA THERAPEUTICS INC | SION | $2.6M | 59,426 | +0.17pp | 2q | -18.7%-$600.6K | |
| ARCUTIS BIOTHERAPEUTICS INC | ARQT | $2.6M | 98,945 | -1.43pp | 11q | -88.0%-$19.1M | |
| C4 THERAPEUTICS INC | CCCC | $2.4M | 523,648 | +0.19pp | 2q | -42.2%-$1.8M | |
| SPRUCE BIOSCIENCES INC | SPRB | $2.2M | 41,388 | +0.30pp | 2q | +225.4%+$1.5M | |
| CUE BIOPHARMA INC | CUE | $2.1M | 66,995 | - | new | NEW | |
| STRUCTURE THERAPEUTICS INC | GPCR | $2.0M | 38,178 | -1.51pp | 4q | -90.5%-$19.4M | |
| PROTAGONIST THERAPEUTICS INC | PTGX | $2.0M | 16,303 | -1.13pp | 7q | -88.8%-$15.8M | |
| HELIX ACQUISITION CORP III | HLXC | $1.8M | 171,671 | -0.28pp | 2q | -71.9%-$4.7M | |
| BIODESIX INC | BDSX | $1.6M | 70,000 | +0.08pp | 2q | -50.0%-$1.6M | |
| TENAX THERAPEUTICS INC | TENX | $1.4M | 96,273 | -0.34pp | 2q | -74.5%-$4.1M | |
| SAB BIOTHERAPEUTICS INC | SABS | $1.3M | 342,631 | -0.05pp | 3q | -54.3%-$1.6M | |
| CALCIMEDICA INC | CALC | $1.2M | 1,244,864 | - | new | NEW | |
| LB PHARMACEUTICALS INC | LBRX | $1.0M | 31,785 | -0.06pp | 2q | -68.2%-$2.2M | |
| CELLECTAR BIOSCIENCES INC | CLRB | $986.7K | 354,938 | - | new | NEW | |
| PROQR THRAPEUTICS N V | PRQR | $801.8K | 431,054 | - | new | NEW | |
| SPDR SERIES TRUST OPT | XBI | $578.0K | options only | +0.07pp | 2q | OPTIONS | |
| ASTRAZENECA PLC OPT | AZN | $180.0K | options only | - | new | OPTIONS | |
| ARK ETF TR OPT | ARKG | $75.0K | options only | - | new | OPTIONS | |
| VISTAGEN THERAPEUTICS INC | VTGN | $17.3K | 616,749 | -0.01pp | 11q | -50.0%-$17.3K | |
| AMGEN INC OPT | AMGN | $15.0K | options only | - | new | OPTIONS |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $545.6M | 94.0% |
| Healthcare Services | $16.0M | 2.8% |
| Other sectors | $1.8M | 0.3% |
| Not classified | $17.1M | 2.9% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $580.5M | 77 | 28 | 7 | 41 | 27 | 41.1% | 45 |
| Q1 2026 | $1.0B | 76 | 37 | 34 | 5 | 36 | 45.8% | 45 |
| Q4 2025 | $583.2M | 75 | 32 | 27 | 16 | 37 | 45.7% | 48 |
| Q3 2025 | $499.1M | 80 | 43 | 18 | 17 | 13 | 51.3% | 45 |
| Q2 2025 | $311.6M | 50 | 17 | 16 | 14 | 24 | 50.1% | 45 |
| Q1 2025 | $313.7M | 57 | 28 | 12 | 15 | 22 | 50.5% | 45 |
| Q4 2024 | $400.6M | 51 | 25 | 18 | 6 | 24 | 50.8% | 45 |
| Q3 2024 | $334.0M | 50 | 21 | 10 | 14 | 13 | 56.2% | 44 |
| Q2 2024 | $340.3M | 42 | 16 | 14 | 10 | 24 | 55.4% | 44 |
| Q1 2024 | $378.3M | 50 | 22 | 16 | 10 | 35 | 57.9% | 131 |
| Q4 2023 | $374.8M | 63 | 0 | 0 | 0 | 0 | 39.6% | 44 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.